Table S4.
Scenario analysis: results of cost-effectiveness analysis using generic drug costs for treatments in composite therapy arm
| Brexpiprazole | Lurasidone | Cariprazine | |
|---|---|---|---|
| Total annual cost per patient (medical + pharmacy costs) | $18,931 | $23,955 | $21,210 |
| Relapses | 0.363 | 0.600 | 0.410 |
| Avoided relapses | 0.637 | 0.400 | 0.590 |
| Hospitalizations | 0.281 | 0.464 | 0.317 |
| Avoided hospitalizations | 0.719 | 0.536 | 0.683 |
| QALYs | 0.707 | 0.623 | 0.683 |
| Change in total cost | −$2,279 | $2,745 | Reference |
| Change in avoided relapses | 0.0467 | −0.191 | Reference |
| Change in avoided hospitalizations | 0.036 | −0.147 | Reference |
| Change in QALYs | 0.0245 | −0.060 | Reference |
| ICER per avoided relapse | Dominant | Dominated | Reference |
| ICER per avoided hospitalization | Dominant | Dominated | Reference |
| ICER per QALY | Dominant | Dominated | Reference |
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.